Home Agtech

agtech

Produce marketplace start-up secures $8m in Series A funding

Full Harvest, a platform that brings together agri markets for excess produce has attracted investment from Cultivian Sandbox Ventures and Spark Capital.

Investors unfazed by transatlantic row over gene-editing

More emerging markets are likely to follow the US’s intent to ‘re-double’ efforts to develop the technology than Europe’s stringent regulatory stance unveiled last week, says Pontifax’s Ben Belldegrun.

What ag should take away from McDonald’s

A family-owned business wants to create a franchise model in dairy farming that it hopes to export overseas. A recipe for success?

Are investors getting ahead of themselves on gene editing?

The technology holds great promise and attracts a lot of money. Whether it will disappoint or thrive, however, depends on which side of the regulation divide it falls.

Pontifax participates in $110m funding round in ninth deal from debut fund

Precision BioSciences will use the capital raised to extend its gene-editing technology from human therapeutics to the agri-food industry.

Food service robot nets $11m

Chowbotics’ founder Deepak Sekar tells Agri Investor why the US robot provider has focused on health and wellness over labor replacement.

Pontifax backs UK gene editing company in $10 million A round

Tropic Biosciences is developing decaffeinated coffee varieties and bananas with a longer shelf life using CRISPR gene editing technology that Pontifax managing partner Ben Belldegrun tells Agri Investor is drawing biotech investors into the market.

Blockchain start-up hopes to foster peer-to-peer lending between farmers

Australia-based BlockGrain says its technology could help growers earn additional revenue while helping others avoid costly bridge loans and overdrafts.

€120m AfricInvest venture fund to back agtech startups

The vehicle targets family offices, DFIs, corporates and foundations as it eyes a first close by the end of the year, VC chief Selma Ribica tells Agri Investor.

Exclusive: Inocucor to hit close on Series B days after debut acquisition

Cash provided by existing investors will be used to seal the ATP deal, which the biostimulant maker's CEO hopes marks the first of a series of strategic purchases.

Copyright PEI Media

Not for publication, email or dissemination